PT  - JOURNAL ARTICLE
AU  - Berec, Luděk
AU  - Šmíd, Martin
AU  - Přibylová, Lenka
AU  - Májek, Ondřej
AU  - Pavlík, Tomáš
AU  - Jarkovský, Jiří
AU  - Zajíček, Milan
AU  - Weiner, Jakub
AU  - Barusová, Tamara
AU  - Trnka, Jan
TI  - Real-life protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in the Czech Republic: a whole country retrospective view
AID  - 10.1101/2021.12.10.21267590
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.10.21267590
4099  - http://medrxiv.org/content/early/2021/12/12/2021.12.10.21267590.short
4100  - http://medrxiv.org/content/early/2021/12/12/2021.12.10.21267590.full
AB  - Background Evidence is accumulating that the effectiveness of covid-19 vaccines against infection wanes, reaching relatively low values after 6 months. Published studies demonstrating this effect based their findings on a limited range of vaccines or subset of populations, and did not include booster vaccine doses or immunity obtained due to covid-19 infection. Here we evaluate effectiveness of covid-19 vaccines, booster doses or previous infection against covid-19 infection, hospital admission or death for the whole population in the Czech Republic.Methods Data used in this study cover the whole population of the Czech Republic reported as infected and/or vaccinated between the first detected case on March 1, 2020 and November 20, 2021 (for reinfections), or December 26, 2020 and November 20, 2021 (for vaccinations), including hospital admissions and deaths. Vaccinations by all vaccines approved in the EU were included in this study. Anonymous, individual-level data including dates of vaccination, infection, hospital admission and death were provided by the the Institute of Health Information and Statistics of the Czech Republic. The risks of reinfection, breakthrough infection after vaccination, hospital admission and death were calculated using hazard ratios from a Cox regression adjusted for sex, age, vaccine type and vaccination status.Findings The vaccine effectiveness against any PCR-confirmed infection declined from 87% (95% CI 86-87) at 0-2 months after the second dose to 53% (95% CI 52-54) at 7-8 months for Comirnaty, from 90% (95% CI 89-91) at 0-2 monthsto 65% (95% CI 63-67) at 7-8 months for Spikevax, and from 83% (95% CI 80-85) at 0-2 months to 55% at (95% CI 54-56) 5-6 months for the Vaxzevria. For Janssen Covid-19 Vaccine we found no significant decline but the estimates are less certain. The vaccine effectiveness against hospital admissions and deaths decayed at a significantly lower rate with about 15%, resp. 10% decline during the first 6-8 months. The administration of a booster dose returns the protection to or above the estimates in the first two months after dose 2. In unvaccinated but previously SARS-CoV-2-positive individuals the protection against PCR-confirmed SARS-CoV-2 infection declined from close to 97% (95% CI 97-97) after 2 months through 90% at 6 months down to 72% (95% CI 65-78) at 18 months.Interpretation Our results confirm the waning of vaccination-induced immunity against infection and a smaller decline in the protection against hospital admission and death. A booster dose is shown to restore the vaccine effectiveness back to the levels seen soon after the completion of the basic vaccination schedule. The post-infection immunity decreases over time, too.Funding No external funding was used to conduct this study.Evidence before this study Accumulating evidence from several countries indicates that the effectiveness of covid-19 vaccines against infection declines in time, from about 80-90% shortly after completing the vaccination to about 50-60% and even less after 6 months. Published studies also suggest a significant boosting in vaccine effectiveness against infection about one week after the third vaccine dose. However, these observations come from different and often limited data sets. Moreover, the existing studies do not compare the decline in vaccine effectiveness with a decline in infection-based immunity in unvaccinated individuals.Added value of this study In our study, we bring together data on infections, vaccinations (including booster doses), hospital admissions and deaths to estimate how the protection due to vaccination or previous SARS-CoV-2 infection declines with time, for the whole population of the Czech Republic. Our findings show an overall decrease in vaccine effectiveness over time and a large increase after the administration of a booster dose. At the same time we show a fairly stable and high post-infection immunity over the study period. We hope this evidence will contribute to a better understanding of the changing impact of vaccines and previous infection in complex, real-world environments, which is crucial for the development of more effective and more easily communicated public health policies.Implications of all the available evidence Our results strongly support a timely and widespread application of booster vaccine doses since their application appears to restore the vaccine-induced protection to the levels attained soon after completing the original vaccination scheme, including the high protection against mild disease or asymptomatic infection.Competing Interest StatementAll other authors declare no competing interests.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data collection was managed and their usage approved by the Institute of Health Information and Statistics of the Czech Republic, according to the rules set by the Ministry of Health of the Czech Republic. According to a decision of the Institute of Health Information and Statistics of the Czech Republic, our retrospective analyses did not require ethical approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData reported in this study and used for the analyses are not public. De-identified individual-level data are available to the scientific community. Requests should be submitted to the Institute of Health Information and Statistics of the Czech Republic (www.uzis.cz/index-en.php), together with a short description of their analysis proposals, where they will be assessed based on relevance and scientific merit.